Michiel Rienstra


Michiel Rienstra is professor of Clinical Cardiology and specializes in atrial fibrillation and heart failure. In 2009, he was awarded with a NWO Rubicon grant and went to Harvard Medical School, Massachusetts General Hospital and the Framingham Heart Study for a post-doc on population genetics and epidemiology. In 2012, he was awarded with the NWO Veni grant for his project on genetics of atrial fibrillation. In 2015, the European Society of Cardiology academic grant supported his project on a big data approach in atrial fibrillation. Currently, professor Rienstra is chairing a research group of (MD-)research fellows, MD-PhD-fellows, post-docs and students mainly on improving diagnosis (including genetics) and treatment of individuals with (or at risk of) atrial fibrillation and the combination of atrial fibrillation and heart failure.

Contact details

Current activities

He is involved in of 4 large national consortia; RACE V (hypercoagulability and AF progression), RED-CVD (early detection of cardiovascular disease in general practices), AI (catalyzing the application of artificial intelligence in CV disease), and MyDigiTwin (Big-data and Artificial Intelligence-based ecosystem to create a user’s personal “Digital Twin”). He is/was involved as principal investigator/ steering committee member of numerous mainly investigator-initiated clinical studies (RACE 2 to 7, MARC 1-2, VIP-HF, DECISION). He is fellow of the European Society of Cardiology and the American Heart Association, and member of the Scientific & Clinical Education Lifelong Learning Committee (SCILL), previous member of the Leadership Committee of the AHA – Genomics and Precision Medicine council. He has authored thus far more than 175 peer-reviewed papers and book chapters.

My projects


EHRA-PATHS: Addressing multimorbidity in elderly atrial fibrillation patients through interdisciplinary, patient-centred, systematic care pathways.


A randomized controlled trial of AV junction ablation and biventricular pacing versus optimal pharmacological therapy in patients with permanent atrial fibrillation


Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands: DECISION


Reappraisal of Atrial Fibrillation: Interaction between hyperCoagulability, Electrical remodeling, and Vascular Destabilisation in the Progression of AF


Comparing early ablation and standard therapy


Improving early detection of CVD


Reversal of Atrial Substrate to Prevent Atrial Fibrillation


Device-based rate versus rhythm control treatment in patients with symptomatic recent-onset atrial fibrillation in the emergency department


Identification of a risk profile to guide atrial fibrillation therapy

Adiposity in Heart Failure with Preserved Ejection Fraction

Epicardial fat can cause heart failure with preserved ejection fraction.


Personalised Medicine in Chronic Disease Management

My publications

Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients

Sophie L van Veldhuisen, Gijs van Woerden, Martin E W Hemels, Yves G C J America, Rudolf A de Boer, Michiel Rienstra, Dirk J van Veldhuisen, Eric J Hazebroek. Surg Obes Relat Dis 2021.

view on PubMed

Epicardial Adipose Tissue and Invasive Hemodynamics in Heart Failure with Preserved Ejection Fraction

Thomas M Gorter, Gijs van Woerden, Michiel Rienstra, Michael G Dickinson, Yoran M Hummel, Adriaan A Voors, Elke S Hoendermis, Dirk J van Veldhuisen. JACC Heart Fail 2020.

view on PubMed

Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.

The objective of this study was to assess the association of digoxin with cardiovascular (CV) morbidity and mortality in patients with permanent atrial fibrillation enrolled in the Dutch Rate Control Efficacy in Permanent AF: A Comparison Between Lenient Versus Strict Rate Control II trial as well as to assess the role of digoxin to achieve heart rate targets. The use of digoxin was not associated with increased morbidity and mortality.

view on Heart Rhythm Journal

Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis.

Heart failure with preserved ejection fraction and AF are very common diseases that also often occur in combination, further aggravating each other. Senile amyloidosis, either due to TTR (ATTRwt) or ANP (IAA) appears to play an important role in both diseases and in their interaction. In terms of diagnostics, bone scintigraphy has become available and affords an easy and reliable way to establish the presence of cardiac ATTRwt. Moreover, pharmacological options are now available or under development to treat ATTRwt and possibly also IAA, thereby potentially stopping, or even reversing, the downhill course of some patients with HFpEF and AF.

view on Oxford Academic

Pulmonary vein anatomy addressed by computed tomography and relation to success of second-generation cryoballoon ablation in paroxysmal atrial fibrillation.

The aim of this study was to assess PV morphology and variants including carina width, shared carina or PV ovality index and whether this is of influence on AF recurrence after PVI with the second generation 28 mm cryoballoon in a homogenous population of patients with paroxysmal AF. No specific characteristics of PV dimensions nor morphology were associated with AF recurrence after cryoballoon ablation in patients with paroxysmal AF.

view on Wiley Online Library